scholarly journals Adherence to non-pharmacological treatment: Analysis of the impact of three health educational and nutritional strategies in hypertensive patients

2016 ◽  
Vol 29 (1) ◽  
pp. 11-22 ◽  
Author(s):  
Juliana Costa MACHADO ◽  
Rosângela Minardi Mitre COTTA ◽  
Tiago Ricardo MOREIRA ◽  
Luciana Saraiva da SILVA
Keyword(s):  
Body Mass Index ◽  
Blood Glucose ◽  
Pharmacological Treatment ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Treatment Of Hypertension ◽  
The Impact ◽  
Nutritional Strategies

ABSTRACT Objective: To evaluate adherence to non-pharmacological treatment of hypertension by comparing biochemical, clinical, anthropometric, and dietary parameters before and after three health educational and nutritional strategies. Methods: This longitudinal clinical trial included 212 hypertensive individuals who met the inclusion criteria. The participants were allocated to three groups to assess the impact of monthly intervention methods over twelve months. Results: Waist circumference decreased significantly in all groups. Weight and body mass index decreased significantly in Groups 2 and 3. Blood glucose, total cholesterol, and low-density lipoprotein cholesterol decreased significantly in Groups 1 and 2. The interventions also reduced the mean per capita intakes of oil, sugar, and salt in all groups. Conclusion: Educational interventions promoted adherence to non-pharmacological treatment of treatment of hypertension evidenced by anthropometric (weight, body mass index, and waist circumference), biochemical (blood glucose, total cholesterol, and low-density lipoprotein cholesterol), and dietary (meanper capita intake of oil, sugar, and salt) parameters.

Effect of Honey & Olive Oil Supplemented Bio-Yoghurt Feeding on Lipid Profile, Blood Glucose and Hematological Parameters in Rats

2019 ◽  
Vol 15 (2) ◽  
pp. 140-147
Author(s):  
Magdy M. Ismail ◽  
El-Tahra M. Ammar ◽  
Abd El-Wahab E. Khalil ◽  
Mohamed Z. Eid
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Blood Glucose ◽  
Olive Oil ◽  
Body Weight Gain ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol

Background and Objective: Yoghurt, especially bio-yoghurt has long been recognized as a product with many health benefits for consumers. Also, honey and olive oil have considerable nutritional and health effects. So, the effect of administration of yoghurt made using ABT culture and fortified with honey (2 and 6%), olive oil (1 and 4%) or honey + olive oil (2+1 and 6+4% respectively) on some biological and hematological properties of rats was investigated.Methods:The body weight gain, serum lipid level, blood glucose level, serum creatinine level, Glutamic Oxaloacetic Transaminase (GOT) activity, Glutamic Pyruvic Transaminase (GPT) activity, leukocytes and lymphocytes counts of rats were evaluated.Results:Blending of bio-yoghurt with rats' diet improved body weight gain. Concentrations of Total plasma Cholesterol (TC), High-Density Lipoprotein cholesterol (HDL), Low-Density Lipoprotein cholesterol (LDL), Very Low-Density Lipoprotein cholesterol (VLDL) and Triglycerides (TG) significantly lowered in plasma of rats fed bio-yoghurt. Levels of TC, LDL, VLDL, and TG also decreased in rat groups feed bio-yoghurt supplemented with honey and olive oil. LDL concentrations were reduced by 10.32, 18.51, 34.17, 22.48, 43.30% in plasma of rats fed classic starter yoghurt, ABT yoghurt, ABT yoghurt contained 6% honey, ABT yoghurt contained 4% olive oil and ABT yoghurt contained 6% honey + 4% olive oil respectively. The blood glucose, serum creatinine, GOT and GPT values of rats decreased while white blood cells and lymphocytes counts increased by feeding bioyoghurt contained honey and olive oil.Conclusion:The findings enhanced the multiple therapeutic effects of bio-yoghurt supplemented with honey and olive oil.

Abstract 14430: Effect Modification of Statin Therapy on the Relationship of Low-density Lipoprotein Cholesterol With Incident CKD in Us Veterans

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Jui-Ting Hsiung ◽  
Maria Marroquin ◽  
Kamyar Kalantar-Zadeh
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Us Veterans ◽  
The Impact ◽  
Statin Use

Background: Studies suggests that in the general population, hyperlipidemia may confer higher risk of developing chronic kidney disease (CKD). But, there is conflicting data as to whether statins can protect renal function or slow renal degradation. We sought to examine the impact of statins on the association of low-density lipoprotein cholesterol (LDL) and risk of incident CKD. Methods: Our cohort included 1,439,756 US veterans without chronic kidney disease (CKD), but with LDL measured between 2004-2006, who were followed until 2014. Incident CKD was defined as over 3 estimated glomerular filtration rate (eGFR) measurements <60 mL/min/1.73m 2 at least 90 days apart. Patients with a statin prescription at the time of LDL measurement were identified. Cox models were used to estimate the associations between LDL with incident CKD. Model adjustments include demographics, comorbidities, smoking status, prescription of fibrate or niacin, body mass index, albumin, high-density lipoprotein cholesterol, and triglycerides. Results: The cohort included 5% females, 16% African Americans, 26% diabetics, and 30% statin-users, with a mean age of 60±13 years. The median [IQR] of LDL and eGFR were 109 [88,133] mg/dL and 83 [72,94] mL/min/1.73m 2 , respectively. A J-shaped association between LDL and incident CKD were observed in both those on statin and not on a statin after adjustment. Low LDL (<70 mg/dL) was associated with a higher risk of incident CKD compared to the reference (LDL 70-<100 mg/dL) regardless of statin use. High LDL ≥160 mg/dL was associated with the highest of risks of incident CKD (HR: 1.08, 95% CI: 1.04, 1.13, and HR: 1.10, 95% CI: 1.07, 1.12, for statin use and no statin use, respectively). Conclusion: Both high and low LDL were associated with higher incident CKD risk independent of statin use in this US veteran cohort. Further studies are needed to understand how to manage cardiovascular disease risk by lowering LDL while simultaneously reducing risk of CKD.

scholarly journals Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events

2020 ◽  
Vol 9 (23) ◽  
Author(s):  
Peter Willeit ◽  
Calvin Yeang ◽  
Patrick M. Moriarty ◽  
Lena Tschiderer ◽  
Stephen A. Varvel ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Clinical Care ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cholesterol Content ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Lipoprotein A ◽  
The Impact

Background Conventional "low‐density lipoprotein cholesterol (LDL‐C)" assays measure cholesterol content in both low‐density lipoprotein and lipoprotein(a) particles. To clarify the consequences of this methodological limitation for clinical care, our study aimed to compare associations of “LDL‐C” and corrected LDL‐C with risk of cardiovascular disease and to assess the impact of this correction on the classification of patients into guideline‐recommended LDL‐C categories. Methods and Results Lipoprotein(a) cholesterol content was estimated as 30% of lipoprotein(a) mass and subtracted from “LDL‐C” to obtain corrected LDL‐C values (LDL‐C corr30 ). Hazard ratios for cardiovascular disease (defined as coronary heart disease, stroke, or coronary revascularization) were quantified by individual‐patient‐data meta‐analysis of 5 statin landmark trials from the Lipoprotein(a) Studies Collaboration (18 043 patients; 5390 events; 4.7 years median follow‐up). When comparing top versus bottom quartiles, the multivariable‐adjusted hazard ratio for cardiovascular disease was significant for “LDL‐C” (1.17; 95% CI, 1.05–1.31; P =0.005) but not for LDL‐C corr30 (1.07; 95% CI, 0.93–1.22; P =0.362). In a routine laboratory database involving 531 144 patients, reclassification of patients across guideline‐recommended LDL‐C categories when using LDL‐C corr30 was assessed. In “LDL‐C” categories of 70 to <100, 100 to <130, 130 to <190, and ≥190 mg/dL, significant proportions (95% CI) of participants were reassigned to lower LDL‐C categories when LDL‐C corr30 was used: 30.2% (30.0%–30.4%), 35.1% (34.9%–35.4%), 32.9% (32.6%–33.1%), and 41.1% (40.0%–42.2%), respectively. Conclusions “ LDL‐C” was associated with incident cardiovascular disease only when lipoprotein(a) cholesterol content was included in its measurement. Refinement in techniques to accurately measure LDL‐C, particularly in patients with elevated lipoprotein(a) levels, is warranted to assign risk to the responsible lipoproteins.

scholarly journals Profil Lipid, Peroksidasi Lipid, dan Status Inflamatif Wanita Penderita Sindrom Metabolik

2011 ◽  
Vol 5 (5) ◽  
pp. 212
Author(s):  
Hery Winarsi ◽  
Siwi P.M. Wijayanti ◽  
Agus Purwanto
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
High Density Lipoprotein ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
C Reactive Protein ◽  
Reactive Protein

Prevalensi sindrom metabolik (SM) di Indonesia (13,13%) tergolong tinggi dengan kecenderungan terus meningkat. Salah satu akibat SM adalah disfungsi endotel, sebagai awal penyakit kardiovaskuler yang diinduksi oleh stres oksidatif dan inflamatif. Penelitian ini bertujuan untuk mengeksplorasiprofil lipid, peroksidasi lipid, dan marker inflamasi pada wanita penderita SM di Purwokerto. Sebanyak 30 wanita dengan kadar gula darah diatas normal, obesitas body mass index (BMI) > 25 kg/m2, dan berusia 40-65 tahun dilibatkan sebagai responden yang dipilih melalui survei di PoliklinikPenyakit Dalam Rumah Sakit Margono Soekarjo. Kadar kolesterol total, trigliserida, high density lipoprotein, low density lipoprotein, malondialdehid, dan plasma C-reactive protein ditentukan dalam darah responden yang mempunyai kadar gula sewaktu > 200 mg/dL. Ditemukan bahwa wanitadengan SM rata-rata berumur 50,4 tahun; BMI 31,89 kg/m2; kadar gula darah 219,4 mg/dL; kolesterol total 216,73 mg/dL; trigliserida 218,13 mg/dL; HDL 46,59 mg/dL; LDL 146,27 mg/dL; MDA 2943,4 pmol/mL; C-RP 7,62 mg/L; dan tekanan darah 153/103 mmHg. Hasil ini menunjukkan bahwapenderita SM mengalami dislipidemia disertai dengan status antioksidan rendah dan inflamasi.Kata kunci: Wanita sindrom metabolik, profil lipid, lipid peroksida, malondialdehid, C-reactive proteinAbstractPrevalence of metabolic syndrome (MS) in Indonesia (13,13%) is high and tends to increase. One of the consequences of MS is endothelial dysfunction leading to cardiovascular disease which is inducted by oxidative stressand inflammation. The aim of the present research is to explore lipid profile, lipid peroxidation, and inflammatory marker level on metabolic syndrome women in Purwokerto. Thirty women with blood glucose level greater than normal, body mass index (BMI) > 25 kg/m2, 40-65 years of age were recruited as respondent through selection by a survey in Internal Medicine Polyclinic of Margono Soekarjo Hospital in Purwokerto. In respondents with blood glucose level > 200 mg/dL, total blood cholesterol level, high density lipoprotein, low density lipoprotein, malondialdehid, and plasma C-reactive protein were determined. It was found that the MS women were 50,4 years of age; BMI 31,89 kg/m2; blood glucose 219,4 mg/dL; total cholesterol 216,73 mg/dL; triglyceride 218,13 mg/dL; HDL 46,59 mg/dL; LDL 146,27mg/dL; MDA 2943,4 pmol/mL; C-RP 7,62 mg/L; and blood pressure 153/103 mmHg. It indicates that SM women experience dyslipidemia with low antioxidant and inflammation.Key words: Metabolic syndrome women, lipid profile, peroxide lipid, malondialdehid, C-reactive protein

scholarly journals Does the Impact of Smoking on Coronary Heart Disease Differ by Low-Density Lipoprotein Cholesterol Level?

2006 ◽  
Vol 70 (9) ◽  
pp. 1105-1110 ◽  
Author(s):  
Atsushi Hozawa ◽  
Aaron R. Folsom ◽  
A. Richey Sharrett ◽  
Thomas J Payne ◽  
Lloyd E. Chambless
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cholesterol Level ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document